Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis (Q92672695)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

review article

1 reference

title

Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

author name string

Steve Kanters

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

Jeroen P Jansen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

Andrew Stewart

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

Susan Sparks

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

Kristina An Haack

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

Anna Bolzani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

Gaye Siliman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

Alaa Hamed

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

publication date

11 June 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

volume

266

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

page(s)

2312-2321

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

Enzymatic Replacement Therapy in Patients with Late-Onset Pompe Disease - 5-Year Follow Up

1 May 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

A conceptual disease model for adult Pompe disease

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease—a long-term follow-up

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

The impact of antibodies in late-onset Pompe disease: a case series and literature review

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

24-months results in two adults with Pompe disease on enzyme replacement therapy.

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Adult Pompe disease: Clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Effect of enzyme therapy in juvenile patients with Pompe disease: A three-year open-label study

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

The 6-min walk distance in healthy subjects: reference standards from seven countries

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

A randomized study of alglucosidase alfa in late-onset Pompe's disease

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Determinants of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC in chronic spinal cord injury

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Interpretative strategies for lung function tests

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Disease severity in children and adults with Pompe disease related to age and disease duration

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

Late-onset Pompe disease primarily affects quality of life in physical health domains

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

ATS/ERS Statement on respiratory muscle testing

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6687674

10.1007/S00415-019-09401-1

11 February 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31187190 AND SRC:MED&resulttype=core&format=json

1 May 2020

PubMed publication ID

31187190

1 reference